Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

573 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial).
van Baak MA, van Mil E, Astrup AV, Finer N, Van Gaal LF, Hilsted J, Kopelman PG, Rössner S, James WP, Saris WH; STORM Study Group. van Baak MA, et al. Among authors: finer n. Am J Clin Nutr. 2003 Aug;78(2):209-14. doi: 10.1093/ajcn/78.2.209. Am J Clin Nutr. 2003. PMID: 12885699 Clinical Trial.
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L; NN8022-1807 Investigators. Astrup A, et al. Among authors: finer n. Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Int J Obes (Lond). 2012. PMID: 21844879 Free PMC article. Clinical Trial.
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, Finer N, James WP, Caterson ID, Rode RA, Torp-Pedersen C; SCOUT Executive Steering Committee; SCOUT investigators. Andersson C, et al. Among authors: finer n. Metabolism. 2009 Aug;58(8):1109-15. doi: 10.1016/j.metabol.2009.04.003. Epub 2009 Jun 18. Metabolism. 2009. PMID: 19454355 Clinical Trial.
Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period.
Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Torp-Pedersen C, Sharma AM, Ge H, Santoro D, Shepherd G, James P; SCOUT Investigators. Caterson I, et al. Among authors: finer n. Obesity (Silver Spring). 2010 May;18(5):987-94. doi: 10.1038/oby.2009.327. Epub 2009 Oct 8. Obesity (Silver Spring). 2010. PMID: 19816415 Free article. Clinical Trial.
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL; SCOUT Investigators. James WP, et al. Among authors: finer n. N Engl J Med. 2010 Sep 2;363(10):905-17. doi: 10.1056/NEJMoa1003114. N Engl J Med. 2010. PMID: 20818901 Free article. Clinical Trial.
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C. Ghotbi AA, et al. Among authors: finer n. Diabetes Care. 2013 Nov;36(11):3746-53. doi: 10.2337/dc13-0027. Epub 2013 Oct 2. Diabetes Care. 2013. PMID: 24089540 Free PMC article. Clinical Trial.
573 results